30-year industry career including large pharma and small biotech leading the development of new medicines in cancer, inflammation, fibrosis, osteoporosis, respiratory and lymphatic disorders. Advanced dozens of therapeutic drug programs from discovery and preclinical development through Phase 1 and beyond. Authored more than 30 scientific publications and 12 therapeutic drug patents. PhD in molecular biophysics. Postdoctoral training in clinical pharmacology and immunology at Vanderbilt University.

30-year biopharmaceutical industry veteran with senior leadership across operations, strategy, M&A, and therapeutic licensing. Proven clinical development leader who has advanced 20+ regulated medical technologies to market under FDA standards, including programs addressing patients with significant unmet medical needs. Broad therapeutic depth spanning cardiology, neurology, oncology, and gene therapy. Recognized dealmaker with a strong record of forging strategic partnerships that accelerate innovation and commercialize breakthrough treatments. Led multiple successful divestitures and product sales to top-tier industry players, including SmithKline, Sanofi, Merck, and Pasteur Merieux.

Allan and Tina Neill Professor of Lymphatic Research and Medicine at Stanford University School of Medicine. A fellow of the American College of Cardiology, American College of Angiology, and American College of Physicians, as well as a member of the International Society of Lymphology, American Society of Internal Medicine, the Society of Vascular Medicine and Biology, and the Paul Dudley White Society. As a principal investigator or co-investigator, he has led numerous clinical trials researching various aspects of lymphatic disease, vascular biology and cardiovascular medicine. Editor-in-Chief of Lymphatic Research and Biology. Co-founder of LE&RN. Medical degree from Duke University School of Medicine, internship and residency training in internal medicine at the Peter Bent Brigham Hospital of Harvard Medical School, and fellowship training in the cardiac unit of Massachusetts General Hospital, Harvard Medical School.

25 years of branded and generic pharma experience covering a full spectrum of dosage forms. Expertise working from discovery to post-marketing phases, with extensive experience managing US and International CRO/CMOs for the manufacturing of cGMP APIs and DP with thorough knowledge of relevant FDA and EMA regulations. Authored 15 FDA, EMA and Health Canada regulatory submissions and was the leader of CMC program for major orphan NDA nasal spray. PhD in Food science with an emphasis on analytical chemistry and toxicology from Rutgers University.

Manages preclinical drug development teams, advises on strategy, and acts as a logistical conduit between client leadership, scientists, SMEs, vendors, and other program stakeholders. Led dozens of therapeutic programs in a wide range of modalities, indications, and stages of development. Ph.D. in molecular biology and biochemistry from Loyola University Chicago.